Premium
Evaluation of Efficacy and Safety of Recombinant Sperm‐Specific Contraceptive Vaccine in Albino Mice
Author(s) -
Goyal Shipra,
Manivannan Boomi,
Kumraj Ganesh R.,
Ansari Abdul S.,
Lohiya Nirmal K.
Publication year - 2013
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12085
Subject(s) - male contraceptive , fertility , placebo , recombinant dna , testosterone (patch) , sperm , andrology , medicine , physiology , gynecology , biology , population , family planning , research methodology , biochemistry , alternative medicine , environmental health , pathology , gene
Problem This study was undertaken to evaluate the efficacy and safety of recombinant SP ‐10 protein for male contraception. Methods of study Adult male mice were divided into five groups. Group I was placebo‐treated control while G roups II – V were immunized with recombinant SP ‐10 protein on day 0 and 21 with different doses (range 25–100 μg). From each G roup, animals were put for mating fertility test. Histological and hematological parameters, sperm characteristics, serum clinical biochemistry and testosterone levels were investigated. Results Group I showed normal fertility. Group II – V showed dose dependent reduction in fertility. In contrast, at higher dose (75 and 100 μg), all animals were sterile for three months. Further, all parameters under investigation in experimental groups were comparable to those of control animals. Conclusion Our study has put forth a proof of concept for male contraception for the first time, which may be considered suitable for contraceptive vaccine development.